The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

In fact, according to a recent survey, over one-quarter (26%) of consumers in the United States plan to take a weight loss drug to achieve their 2025 New Year's resolution goals. This trend and ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent increase from 2023, according to a Globe analysis of insurance claims data.

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from ...

For more than a year, I have been reporting on the ways that weight-loss drugs like Ozempic affect identity ... for more than seven hours over a period of several weeks. They thoughtfully answered ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

A well-known class of drugs used to manage type 2 diabetes and control weight could offer ... Florida College of Medicine. Over the study period of almost two years, the data showed significant ...